Antiplatelet Management for Coronary Heart Disease: Advances and Challenges

Michael Gillette, Kathleen Morneau, Vu Hoang, Salim Virani, Hani Jneid

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Coronary heart disease (CHD) remains the leading cause of death in the USA. CHD accounts for 48 % of all cardiovascular mortality or approximately one of every seven deaths. Disruption of atherosclerotic plaques—usually by rupture or erosion—and superimposed thrombosis can result in acute coronary syndromes and sudden cardiac death. Silent plaque disruption may also occur and result in coronary plaque progression and ultimately the symptomatic manifestations of stable CHD. Antiplatelet agents remain the cornerstone therapy for acute thrombotic coronary syndromes and are essential for thromboprophylaxis against these events in patients with stable CHD. Antiplatelet drugs are also important adjunct therapies during percutaneous coronary intervention (PCI) as they mitigate equipment-associated thrombotic complications that are partially induced by iatrogenic plaque rupture by interventionalists during balloon angioplasty in the cardiac catheterization laboratory. Since the introduction of clopidogrel, there has been considerable development in this field with at least three novel P2Y12 antagonists approved by the Food and Drug Administration (FDA) over the past decade. Rapidly accumulating evidence is helping to guide the optimal duration of treatment with dual antiplatelet therapy after stenting, especially with the newer drug-eluting stents. More data are also emerging on the hazards and long-term safety of these agents. It is therefore prudent for clinicians to remain current on treatment options and recent advances in this area. We herein review current and emerging antiplatelet therapies and summarize their characteristics and indications of use as well as challenges and areas of ongoing research.

Original languageEnglish (US)
Article number35
JournalCurrent Atherosclerosis Reports
Volume18
Issue number6
DOIs
StatePublished - Jun 1 2016
Externally publishedYes

Keywords

  • Acute coronary syndrome
  • Aggregation
  • Angina
  • Clinical trial
  • Coronary
  • Platelet
  • Thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Antiplatelet Management for Coronary Heart Disease: Advances and Challenges'. Together they form a unique fingerprint.

Cite this